Gossamer Bio takes $25M upfront in deal tied to FDA review of lead drug
What's the deal? San Diego-based Gossamer Bio has received about $25 million in gross proceeds from the initial closing of a structured private placement, the clinical-stage biopharmaceutical company said alongside its third-quarter results. The post-IPO equity financing could reach up to roughly $250 million in total.
Why now? The timing follows Gossamer's first-ever New Drug Application, submitted to the US Food and Drug Administration in September 2026 for seralutinib in pulmonary arterial hypertension (PAH). FDA acceptance of that filing in 2026 would unlock up to about $125 million in additional committed capital.
What's the endgame? Seralutinib is an inhaled treatment Gossamer is developing for PAH and related lung conditions. The company reacquired worldwide development and commercial rights from Chiesi Farmaceutici in July 2026, giving it full control of the program — and more of the development and commercialisation burden.
By the numbers: Gossamer held $51.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026. A further $100 million of gross proceeds could come from warrants, but only if the FDA approves seralutinib and holders exercise in cash.
What could go wrong? The NDA rests on the Phase 3 PROSERA Study, whose primary endpoint did not meet the prespecified statistical threshold, plus confirmatory evidence from the Phase 2 TORREY Study. The FDA has yet to decide whether to accept the application for filing, and most of the financing is contingent on regulatory milestones.
What else? Gossamer completed a 1-for-80 reverse stock split in September 2026 to regain compliance with Nasdaq's minimum bid price requirement, with shares still trading under the symbol GOSS.
"Submitting our first NDA marks an important milestone for Gossamer," said chairman, co-founder, and chief executive officer Faheem Hasnain, adding the company remains focused on "preparing for a potential commercial launch of seralutinib in 2027."
The signal: The structure ties most of Gossamer's capital to regulatory progress, leaving its runway dependent on an FDA that must weigh a missed primary endpoint against the company's confirmatory evidence.
Read more: marketscreener.com
Image credit: nenad53